371 related articles for article (PubMed ID: 10589362)
21. [Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis].
Wiland P; Głowska A; Chlebicki A; Szechiński J
Pol Arch Med Wewn; 2002 Nov; 108(5):1055-63. PubMed ID: 12685246
[TBL] [Abstract][Full Text] [Related]
22. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients.
Köller MD; Aletaha D; Funovits J; Pangan A; Baker D; Smolen JS
Rheumatology (Oxford); 2009 Dec; 48(12):1575-80. PubMed ID: 19812228
[TBL] [Abstract][Full Text] [Related]
23. [Infliximab in the treatment of rheumatoid arthritis].
Akahoshi T; Watabe H
Nihon Rinsho; 2002 Dec; 60(12):2378-83. PubMed ID: 12510365
[TBL] [Abstract][Full Text] [Related]
24. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy.
Mori S
Mod Rheumatol; 2007; 17(2):83-91. PubMed ID: 17437161
[TBL] [Abstract][Full Text] [Related]
25. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
26. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
Oliveira RD; Fontana V; Junta CM; Marques MM; Macedo C; Rassi DM; Passos GA; Donadi EA; Louzada-Junior P
J Rheumatol; 2012 Aug; 39(8):1524-32. PubMed ID: 22753658
[TBL] [Abstract][Full Text] [Related]
27. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
[TBL] [Abstract][Full Text] [Related]
28. Infliximab treatment of rheumatoid arthritis.
Maini SR
Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis.
Ingegnoli F; Fantini F; Griffini S; Soldi A; Meroni PL; Cugno M
Clin Exp Rheumatol; 2010; 28(2):254-7. PubMed ID: 20483049
[TBL] [Abstract][Full Text] [Related]
30. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis.
Bejarano V; Conaghan PG; Quinn MA; Saleem B; Emery P
Rheumatology (Oxford); 2010 Oct; 49(10):1971-4. PubMed ID: 20595536
[TBL] [Abstract][Full Text] [Related]
31. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis.
Taylor PC; Steuer A; Gruber J; McClinton C; Cosgrove DO; Blomley MJ; Marsters PA; Wagner CL; Maini RN
Arthritis Rheum; 2006 Jan; 54(1):47-53. PubMed ID: 16385521
[TBL] [Abstract][Full Text] [Related]
32. Infliximab in active early rheumatoid arthritis.
Breedveld FC; Emery P; Keystone E; Patel K; Furst DE; Kalden JR; St Clair EW; Weisman M; Smolen J; Lipsky PE; Maini RN
Ann Rheum Dis; 2004 Feb; 63(2):149-55. PubMed ID: 14722203
[TBL] [Abstract][Full Text] [Related]
33. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
[TBL] [Abstract][Full Text] [Related]
34. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
[TBL] [Abstract][Full Text] [Related]
35. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
[TBL] [Abstract][Full Text] [Related]
36. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
Smolen JS; van der Heijde DM; Aletaha D; Xu S; Han J; Baker D; St Clair EW
Ann Rheum Dis; 2009 Oct; 68(10):1535-40. PubMed ID: 18957487
[TBL] [Abstract][Full Text] [Related]
37. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
38. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis.
Kageyama Y; Kobayashi H; Kato N
Mod Rheumatol; 2009; 19(6):657-62. PubMed ID: 19685204
[TBL] [Abstract][Full Text] [Related]
39. Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.
Bergman M; De G; Ganguli A; Signorovitch J; Bao Y
J Med Econ; 2015 Jan; 18(1):37-44. PubMed ID: 24841451
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.
Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M
Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
